Clinical Trials Browser

OTHER × Interventional × Paraganglioma × Clear all

NCT06607692 2026-04-14

LUPARPED

Phase 1/2 Recruiting

CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1 Recruiting

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT03839498 2026-03-02

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma

NCT03946527 2026-03-02

LAMPARA

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma

NCT05636540 2026-02-27

In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma

Phase EARLY_PHASE1 Recruiting

Paraganglioma, Pheochromocytoma

NCT01022515 2026-02-06

PHEO

Phase NA Completed

Essential Hypertension, Hypertension, Paraganglioma, Pheochromocytoma

NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Phase 2 Active not recruiting

157 enrolled 26 charts

CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

NCT07288931 2025-12-17

Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma

Phase NA Recruiting

Paraganglioma, Pheochromocytoma

NCT04081701 2025-11-21

DOMINO-START

Phase 4 Recruiting

Medulloblastoma, Meningioma, Paraganglioma, Pituitary Neoplasms, Central Nervous System Neoplasms, Esthesioneuroblastoma, Olfactory, Hemangioblastoma

NCT07167329 2025-09-11

BELIEVE-VHL

Phase 2 Recruiting

CNSEndocrineGenitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

NCT06683846 2025-08-24

Ivonescimab in the Treatment of Multiple Advanced Tumors

Phase 2 Recruiting

CNSDermatologicEndocrineGenitourinarySarcoma

Urachal cancer, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Transitional Cell, Kidney Neoplasms, Paget Disease, Extramammary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Prostatic Neoplasms, Rhabdomyosarcoma, Sarcoma, Angiomyolipoma, Carcinoma, Neuroendocrine, Perivascular Epithelioid Cell Neoplasms

NCT02302833 2025-07-31

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

Phase 2 Completed

21 enrolled 7 charts

Paraganglioma, Pheochromocytoma

NCT06377033 2025-07-20

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

Phase NA Recruiting

Alzheimer Disease, Paraganglioma, Parkinson Disease, Pheochromocytoma, Polyneuropathies, Aortic Aneurysm, Thoracic, Genetic Predisposition to Disease, Frontotemporal Dementia

NCT04400474 2025-06-19

CABATEN

Phase 2 Completed

93 enrolled 17 charts

CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

NCT05702944 2025-06-12

The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma

Phase 4 Recruiting

Paraganglioma, Pheochromocytoma

NCT00843037 2024-10-17

SNIPP

Phase 2 Completed

25 enrolled 19 charts

Neoplasm Metastasis, Paraganglioma, Pheochromocytoma

NCT06045260 2024-08-13

LUFOR

Phase 2 Recruiting

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04860700 2024-06-12

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Phase 2 Completed

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT04605848 2024-05-09

MICROBAT

Phase NA Terminated

Paraganglioma, Pheochromocytoma

NCT05069220 2024-03-01

18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

Phase EARLY_PHASE1 Recruiting

CNSEndocrineNET

Neuroblastoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT03176693 2023-11-20

Preoperative Alpha Blockade for Pheochromocytoma

Phase 3 Completed

39 enrolled 8 charts

Paraganglioma, Pheochromocytoma

NCT05885386 2023-06-01

A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL

Phase 2 Unknown

Paraganglioma, Pheochromocytoma

NCT05883085 2023-05-31

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Phase 2 Unknown

Paraganglioma, Pheochromocytoma

NCT05858177 2023-05-15

MPPGL

Phase 2 Completed

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT02186678 2023-04-06

DOTATATE

Phase NA Completed

Paraganglioma, Pheochromocytoma

NCT00442533 2023-04-03

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Phase 2/3 Completed

CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Somatostatinoma, Neuroendocrine Tumors

NCT04276597 2023-03-10

PUTNET

Phase 2 Withdrawn

CNSDermatologicEndocrineNET

Neoplasms, Unknown Primary, Paraganglioma, Pheochromocytoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT01371201 2022-08-04

FIRSTMAPPP

Phase 2 Completed

Paraganglioma

NCT05133349 2021-11-24

EASOAIPPGL

Phase 2 Unknown

Paraganglioma, Pheochromocytoma

NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

Phase 1/2 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT00843531 2020-09-29

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

Phase 2 Terminated

17 enrolled 10 charts

CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Phase 2 Withdrawn

CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

NCT03344016 2020-07-09

MUPPET

Phase NA Recruiting

Paraganglioma, Pheochromocytoma

NCT01347307 2020-06-18

Stereotactic Body Radiotherapy for Spine Tumors

Phase NA Completed

38 enrolled 11 charts

CNSEndocrineSarcoma

Arteriovenous Malformations, Chordoma, Meningioma, Neurilemmoma, Neurofibroma, Paraganglioma

NCT01635907 2020-04-14

Dovitinib in Neuroendocrine Tumors

Phase 2 Completed

Paraganglioma, Pheochromocytoma

NCT04029428 2020-04-01

POLNETS_PRRT

Phase 2 Unknown

CNSEndocrineNET

Paraganglioma, Neuroendocrine Tumors

NCT02177773 2019-11-12

DOTA-TOC

Phase 1/2 Terminated

300 enrolled 5 charts

CNSEndocrineNET

Carcinoid Tumor, Neuroblastoma, Paraganglioma, Neuroendocrine Tumors

NCT02672020 2019-09-24

COMETETACTIC

Phase NA Completed

Adrenal Gland Neoplasms, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma

NCT01413503 2018-09-18

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

Phase 2 Completed

50 enrolled 7 charts

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

NCT01941849 2015-12-21

VIBRaNT

Phase 1 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors